CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design

Table 2

Current CSF biomarker studies of Alzheimer’s disease.

Acronym	Study name	Study institution and location
ACS	Adult Children Study	Washington University in St. Louis, USA
ADNI	Alzheimer’s Disease Neuroimaging Initiative	University of Pennsylvania*, USA
ARWiBo	Alzheimer’s Disease Repository Without Borders^mc	National Alzheimer Centre, Italy
API-BIO	Alzheimer’s Prevention Initiative	University of Antioquia, Colombia, and Banner Alzheimer’s Institute, USA
	Amsterdam Dementia Cohort^mc	VU University Medical Center, The Netherlands
	Arizona APOE Cohort Study	Banner Alzheimer’s Institute, USA
AIBL	Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing	The Florey Institute of Neuroscience and Mental Health and Edith Cowan University, Australia
BIOCARD	Biomarkers for Older Controls At Risk for Dementia	The Johns Hopkins University, USA
DESCRIPA	Development of Screening Guidelines and Criteria for Predementia Alzheimer’s Disease	University of Maastricht, The Netherlands
DIAN	Dominantly Inherited Alzheimer Network	Washington University in St. Louis*, USA
DNC	German Dementia Competence Network^mc	University Erlangen*, Germany
	Gothenburg MCI Study^mc	University of Gothenburg, Sweden
HASD	Healthy Aging and Senile Dementia	Washington University in St. Louis, USA
MCSA	Mayo Clinic Study of Aging	Mayo Clinic, Rochester, USA
PLM	Paris-North, Lille and Montpellier Study^mc	CMRR: Centres M’emoire de Ressources et de Recherche, France
	Unit for Memory Disorders^mc	Lund University, Sweden
WRAP	Wisconsin Registry for Alzheimer’s Prevention	University of Wisconsin, Madison, USA

*Coordinating Center.
^mcMemory clinic.